Shares of Innate Pharma SA (OTCMKTS:IPHYF) were up 0.6% during trading on Tuesday . The stock traded as high as $7.95 and last traded at $7.95, approximately 1,000 shares were traded during trading. An increase of 432% from the average daily volume of 188 shares. The stock had previously closed at $7.90.
Several brokerages have recently weighed in on IPHYF. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Innate Pharma in a research note on Monday, June 24th. Zacks Investment Research downgraded shares of Innate Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, July 17th.
The firm has a market cap of $457.92 million, a PE ratio of 132.50 and a beta of -0.13. The business’s 50-day simple moving average is $6.77 and its 200 day simple moving average is $6.73.
Innate Pharma SA, a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. It offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas; Monalizumab, a checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications, as well as in Phase I/II clinical trial for the treatment of solid tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils.
See Also: What are Bollinger Bands?
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.